临床肿瘤学杂志

• 论著 • 上一篇    下一篇

血清miR-143水平与晚期胃癌含紫杉醇化疗方案敏感性的关系分析

李金凤,成伟丽,任旭升,李湘红,李大鹏   

  1. 06600 河北秦皇岛 秦皇岛市第四医院胃肠肿瘤科
  • 收稿日期:2016-12-02 修回日期:2017-01-09 出版日期:2017-02-28 发布日期:2017-02-28

Relationship between serum miR-143 level and the sensitivity of paclitaxel-based chemotherapy regimen in advanced gastric cancer

LI Jinfeng,CHENG Weili,REN Xusheng,LI Xianghong,LI Dapeng.   

  1. Department of Gastrointestinal Oncology,the fourth hospital of Qinhuangdao,Qinhuangdao 06600,China
  • Received:2016-12-02 Revised:2017-01-09 Online:2017-02-28 Published:2017-02-28

摘要: 目的 探讨晚期胃癌血清microRNA-143(miR-143)水平与含紫杉醇方案化疗敏感性的关系。方法 收集本院2012年1月至2016年7月收治的82例晚期胃癌患者,均接受含紫杉醇联合铂类或氟尿嘧啶类药物,收集其化疗前的血清标本并采用实时荧光定量PCR(QPCR)法检测其miR-143水平,与同期76例健康体检者的miR-143水平进行比较;分析不同miR-143水平与临床病理特征的关系,采用RECIST1.1版标准评价近期疗效并比较不同miR-143水平与化疗敏感性的关系,根据随访资料比较不同miR-143水平的中位无进展生存期(PFS)和总生存期(OS)。结果 QPCR检测发现82例胃癌患者的miR-143水平为0.215±0.021,低于76例健康体检者的1.099±0.057,差异有统计学意义(P<0.05)。血清miR-143水平与性别、年龄、ECOG评分、肿瘤部位及病理类型均无关,但与TNM分期和分化程度有关,差异有统计学意义(P<0.05)。化疗敏感(CR+PR)31例患者的血清miR-143水平为0.341±0.040,高于化疗抵抗(SD+PD)51例患者的0.138±0.015,差异有统计学意义(P<0.05)。以miR-143水平的中位值(0.177)将患者分为高表达组(>0.177)和低表达组(≤0.177),高表达组的总有效率、中位PFS和OS分别为48.8%、8.5个月和12.2个月,优于低表达组的31.7%、7.3个月和9.4个月,差异有统计学意义(P<0.05)。结论 晚期胃癌血清miR-143水平低于正常值,且与含紫杉醇方案化疗敏感性及预后均有关,其中miR-143高表达者的敏感性较高且预后较好,在胃癌诊断及预后评估上有一定价值。

Abstract: Objective To investigate the relationship between serum microRNA-143 (miR-143) level and chemosensitivity to paclitaxel in patients with advanced gastric cancer. Methods A total of 82 patients with advanced gastric cancer treated with paclitaxel-based regimen in our hospital from January 2012 to July 2016 were enrolled. Serum samples were collected before chemotherapy and their miR-143 levels were detected by qPCR method, and then compared with 76 healthy persons in the same period of miR-143. The relationship between different miR-143 levels and clinical pathological characters were analyzed. RECIST1.1 standard was used to evaluate the short-term efficacy and the relationship between different levels of miR-143 and chemosensitivity were evaluated. Median progression free disease (PFS) and survival (OS) were compared between different miR-143 levels according to follow-up data. Results The qPCR detection showed that the miR-143 level of 82 patients with gastric cancer was (0.215±0.021), lower than those of the healthy subjects (1.099±0.057), and the difference was statistically significant (P<0.05). Serum miR-143 level was not related to sex,age, ECOG score, tumor location and pathological type, but with TNM stage and differentiation degree,and the difference was statistically significant (P<0.05). The serum miR-143 level of 31 patients with chemotherapy sensitive (CR+PR) was (0.341±0.040), which was higher than that of chemotherapy resistance (SD+PD)in patients (0.138± 0.015),and the difference was statistically significant (P<0.05). The patients were divided into high expression group (>0.177) and low expression group (≤0.177) according to the medium value. The response rate, median PFS and OS in the high expression group were 48.8%, 8.5 and 12.2 months, significantly better than those in the low expression group (31.7%, 7.3 and 9.4 months), and the difference was statistically significant (P<0.05). Conclusion The serum miR-143 level of advanced gastric cancer is lower than normal, and related to the paclitaxel chemotherapy sensitivity and prognosis. High expression of miR-143 had a higher sensitivity and better prognosis,showing a certain value in the diagnosis and prognosis of gastric cancer.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!